Fondazione G.B. Bietti, IRCCS

Quick facts

Marketed products

• tafluprost/timolol · Ophthalmology
  Tafluprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor, while timolol is a non-selective beta-blocker that decreases aqueous humor production, together reducing intraocular pressure.

Phase 2 pipeline

• Ranibizumab; Verteporfin

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Fondazione G.B. Bietti, IRCCS portfolio CI brief
• Fondazione G.B. Bietti, IRCCS pipeline updates RSS